PHAT实时信号 | 通过Getagraph.com最大化利润

购买 107444 min ago

@ $6.57

发出时间: 15 Feb 2024 @ 02:56

回报率: 39.73%

上一信号: Feb 14 - 04:47

上一信号: 出售

回报率: 5.80 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases...

Stats
今日成交量	370 890
平均成交量	887 982
市值	536.82M
EPS	$0 ( 2024-03-07 )
下一个收益日期	( $-1.130 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.34
ATR14	$0.0150 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Henderson Molly	Sell	3 435	Common Stoock
2024-03-22	Curran Terrie	Sell	16 851	Common Stock
2024-01-24	Medicxi Ventures Management (jersey) Ltd	Buy	0	Common Stock
2024-01-24	Medicxi Ventures Management (jersey) Ltd	Buy	0	Common Stock
2024-01-24	Medicxi Ventures Management (jersey) Ltd	Buy	0	Common Stock

INSIDER POWER
-49.45
Last 93 transactions
Buy: 9 929 521 \| Sell: 11 759 720

音量相关性

長: -0.14 (neutral)

短: -0.29 (neutral)

Signal:(48.536) Neutral

Phathom Pharmaceuticals 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Phathom Pharmaceuticals 相关性 - 货币/商品

-0.22
( neutral )

-0.07
( neutral )

0.00
( neutral )

0.21
( neutral )

0.62
( weak )

0.64
( weak )

Phathom Pharmaceuticals 财务报表

Annual	2023
营收:	$682 000
毛利润:	$515 000 (75.51 %)
EPS:	$-3.93

FY	2023
营收:	$682 000
毛利润:	$515 000 (75.51 %)
EPS:	$-3.93

FY	2022
营收:	$0
毛利润:	$-620 000 (0.00 %)
EPS:	$-5.70

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.86

Financial Reports:

No articles found.

Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.